Bicara Therapeutics (BCAX) Expected to Announce Earnings on Thursday

Bicara Therapeutics (NASDAQ:BCAX) is expected to release its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect Bicara Therapeutics to post earnings of ($0.72) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 30, 2026 at 8:30 AM ET.

Bicara Therapeutics Trading Down 0.1%

NASDAQ:BCAX opened at $18.39 on Tuesday. The firm has a market capitalization of $1.01 billion, a PE ratio of -8.21 and a beta of -0.78. The stock has a 50 day moving average of $17.00 and a 200-day moving average of $16.38. Bicara Therapeutics has a 52 week low of $7.80 and a 52 week high of $20.25.

Analysts Set New Price Targets

Several brokerages recently issued reports on BCAX. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, January 9th. UBS Group reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Mizuho upgraded Bicara Therapeutics to a “hold” rating in a research note on Thursday, December 18th. Citigroup initiated coverage on shares of Bicara Therapeutics in a report on Thursday, January 29th. They set an “outperform” rating for the company. Finally, Wedbush restated an “outperform” rating and set a $30.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, January 13th. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $30.25.

Insiders Place Their Bets

In related news, CEO Claire Mazumdar sold 36,766 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $19.17, for a total value of $704,804.22. Following the sale, the chief executive officer directly owned 339,392 shares in the company, valued at $6,506,144.64. This trade represents a 9.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Ivan Hyep sold 13,555 shares of Bicara Therapeutics stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $18.22, for a total value of $246,972.10. Following the sale, the chief financial officer directly owned 145,355 shares in the company, valued at $2,648,368.10. The trade was a 8.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 128,769 shares of company stock valued at $2,415,814.

Institutional Investors Weigh In On Bicara Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. grew its position in Bicara Therapeutics by 596.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock valued at $54,472,000 after buying an additional 2,771,868 shares in the last quarter. Invesco Ltd. increased its stake in Bicara Therapeutics by 20.6% during the 4th quarter. Invesco Ltd. now owns 21,006 shares of the company’s stock valued at $354,000 after buying an additional 3,595 shares during the period. VARCOV Co. bought a new stake in shares of Bicara Therapeutics during the 4th quarter worth about $263,000. Virtus Investment Advisers LLC raised its position in shares of Bicara Therapeutics by 46.4% during the 4th quarter. Virtus Investment Advisers LLC now owns 14,395 shares of the company’s stock worth $242,000 after buying an additional 4,560 shares in the last quarter. Finally, Tudor Investment Corp ET AL lifted its stake in shares of Bicara Therapeutics by 46.2% in the 4th quarter. Tudor Investment Corp ET AL now owns 27,391 shares of the company’s stock worth $461,000 after acquiring an additional 8,661 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.